# Progress Note 05 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Marcus Aurelius (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-AC004-SYN-TD
- Date: 0174-07-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Octavia Ashworth-Nnamdi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Mr. Aurelius is a 53-year-old man with reflux esophagitis diagnosed ten weeks ago, on omeprazole, chronic insomnia in cognitive behavioral therapy, and long-standing use of an opium-containing herbal paste, who comes for the preventive visit booked at intake. The COVID-19 illness three weeks ago settled in five days without antiviral treatment; the cough has gone and his energy is back. He took no extra remedy while ill and used no cough syrup. He finished the eight-week omeprazole course two weeks ago and has taken it on demand twice since, each time after a late dinner; otherwise he has no reflux symptoms, and he eats his main meal earlier. He has taken the paste on alternate nights since early June; he has decided that from tonight he will take a smaller amount on only two nights a week. He has never had colorectal cancer screening or a pneumococcal or shingles vaccine. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 53 |
| COVID-19 | Resolved after five days; no antiviral |
| Reflux | Eight-week omeprazole course finished two weeks ago; on demand twice since |
| Mood | PHQ-2 1 |

## Health risk assessment

Completed by the patient on a tablet in the waiting room and reviewed with him by Dr. Ashworth-Nnamdi. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, better than in the spring |
| Psychosocial | Heavy responsibility at work; delegates more after the evening meal; trusted colleagues |
| Substance use | AUDIT-C 2; the herbal paste on alternate nights, about two nights a week from today; no other drugs |
| Tobacco | Never |
| Physical activity | Walks and rides most days, more than 150 minutes a week |
| Nutrition | Two meals a day, the main meal now early in the evening; bread, vegetables, fish and olive oil |
| Sleep | About six hours, improving with CBT-I |
| Safety | Wears a seat belt; no firearms in his quarters; naloxone at the bedside |
| Sexual health | No concerns |
| Activities of daily living | Independent |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy back; weight up 1.4 kg since intake |
| Eyes | Negative | No change in vision; uses reading glasses |
| Ears, nose, mouth, and throat | Negative | No hearing loss or sore throat |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Heartburn twice in two weeks after late dinners, eased by omeprazole; no pain after meals, difficulty swallowing, or blood in the stool; soft stools on the laxative |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash or changing moles |
| Endocrine | Negative | No thirst or frequent urination |
| Psychiatric | Negative | Mood steady; PHQ-2 1 |

11 systems reviewed. **S**

## Current medications

- Polyethylene glycol 3350 powder, 17 g dissolved in a glass of water by mouth once daily as needed for constipation **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeated in 2 to 3 minutes in the other nostril if there is no response; call 911 **S**
- Omeprazole 20 mg delayed-release capsule, one capsule by mouth before breakfast on days after heartburn returns (on-demand therapy after the eight-week course) **S**
- Opium-containing compounded herbal paste (unregulated, strength unknown), a smaller amount, about 0.3 g, by mouth at bedtime on about two nights a week, a further reduction he chose **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 64.4 kg; BMI 21.8 kg/m². All vital signs are synthetic.

PHQ-2: 1; AUDIT-C: 2. All results are synthetic.

## Change since baseline

- AUDIT-C: 3 at baseline, 2 at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine, 20-valent (PCV20), single dose for an adult aged 50 or older **S**
- Recombinant zoster vaccine (RZV), dose 1 of 2 **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 64.4 kg, BMI 21.8; blood pressure 118/76, pulse 70 |
| Skin | No suspicious moles |
| Neck | Thyroid normal; no lymph nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Soft and non-tender; no mass |
| Psychiatric | Engaged and calm |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. PCV20, the first recombinant zoster dose and the first hepatitis B dose given; HIV, hepatitis B and hepatitis C screening sent. Lipids at intake with a coronary calcium score of 0 and no plaque on CT put his ten-year risk low, so no statin is advised. Colonoscopy ordered. **S**
   - Second zoster dose in two to six months.
   - Second hepatitis B dose at the next visit.
   - Influenza vaccine in the autumn; COVID-19 vaccine about three months after the infection.
   - Next preventive visit in one year.
2. **COVID-19, resolved** (U07.1). Recovered in five days without antiviral treatment; no lingering cough or breathlessness. **S**
   - No further action.
3. **Opium-containing remedy** (F11.90). Alternate nights until now, with no extra use during the illness; from tonight, by his own choice, a smaller amount on about two nights a week. A night or two of lighter sleep may follow, as before. Before colonoscopy the bowel preparation needs extra time because the opioid slows the bowel. **S**
   - About two nights a week, a smaller amount, as he has chosen; never a larger amount after nights off.
   - Two extra days of polyethylene glycol before the bowel preparation, and no remedy the night before the colonoscopy.
   - Review the change at the next visit in four weeks.

## Medication changes

- Stopped: Opium-containing compounded herbal paste (unregulated, strength unknown), about 0.5 g by mouth at bedtime on alternate nights, a reduction he chose and made himself **S**
- Started: Opium-containing compounded herbal paste (unregulated, strength unknown), a smaller amount, about 0.3 g, by mouth at bedtime on about two nights a week, a further reduction he chose **S**
- Stopped: Acetaminophen 500 mg oral tablet, one or two tablets by mouth every six hours as needed for fever or aches, no more than 3 g a day **S**

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 118/76 mmHg |
| Depression screening | Completed today | PHQ-2 score 1 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 2 |
| Tobacco use | Completed today | Never smoked |
| Lipid screening and statin assessment | Up to date | Lipids at intake (LDL 133 mg/dL, lipoprotein(a) 38 nmol/L); coronary calcium score 0 and no plaque on CT; low ten-year risk; no statin |
| Diabetes screening | Up to date | A1c 5.4% at intake |
| Colorectal cancer screening | Ordered | Never screened; colonoscopy ordered, with extra bowel preparation because of the opioid |
| Prostate cancer screening | Not indicated | An individual decision from 55; to be discussed then |
| Lung cancer screening | Not indicated | Never smoked |
| HIV screening | Completed today | Once for adults 15 to 65; sent today |
| Hepatitis C screening | Completed today | Once for adults 18 to 79; sent today |
| Hepatitis B screening | Completed today | Once for all adults; sent today before the first vaccine dose |
| Pneumococcal vaccine | Completed today | PCV20, one dose, at 50 or older |
| Zoster vaccine | Completed today | Recombinant zoster vaccine, dose 1 of 2 |
| Hepatitis B vaccine | Completed today | Dose 1 of 2 today, dose 2 at the next visit |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap about six years ago by his report; next in about four years |
| Influenza vaccine | Due | In the autumn |
| COVID-19 vaccine | Due | Due about three months after the infection three weeks ago |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He wants full treatment for any condition from which he could recover to his present life and work, and does not want his life prolonged by machines if he could not. He named a health care agent, recorded in the confidential part of the chart and not named here, and will write his wishes down in his own words. To be revisited yearly. **S**

## Guideline basis

- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Fifteen-week review as planned, with PHQ-9, GAD-7, the Insomnia Severity Index and the second hepatitis B dose. HIV and hepatitis results by phone. Colonoscopy as ordered. Next preventive visit in one year. **S**
- Next scheduled visit 0174-08-25: fifteen-week review after the eight-week omeprazole course: on-demand therapy, sleep, the remedy, and mood. **S**
